Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 103,211

Document Document Title
WO/2014/108514A1
Disclosed herein is a novel and stable salt of tapentadol, tapentadol maleate, its polymorphic Forms as well as processes for its preparation, pharmaceutical compositions, and preparation thereof.  
WO/2014/107794A1
The presently disclosed invention and particular invention embodiments relate to formulations, methods, procedures, and combinations thereof for treating numerous types of trauma-induced and other neurological disorders and injuries, suc...  
WO/2014/109414A1
A compound represented by general formula [1] or a salt thereof. (In general formula [1], Z1 represents a group such as N or CH; X1 represents a group such as NH; R1 represents a group such as a heteroaryl group; R2, R3, and R4 represent...  
WO/2014/109296A1
Disclosed is a compound represented by formula (1) or a salt thereof. In formula (1): X represents a residue of a compound having an activity to bind to at least one member selected from the group consisting of amyloid β protein, a tau ...  
WO/2014/110103A1
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharma...  
WO/2014/108807A3
Novel formulations, procedures and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically act...  
WO/2014/106861A1
The present, invention relates to novel the (4E)-4-(4-substituted benzylideneamino)- 2,3-dihydro-3-substituted -2-thioxothiazole-5-carbonitriles of general formula A and a process for the preparation thereof. The compounds of present inv...  
WO/2014/106660A1
The present invention relates to benzodioxane-piperidine derivatives corresponding to general formula I: in which in particular: -R1 is one or more identical or different substituent(s) on the benzene ring, each being independently a hyd...  
WO/2014/107686A1
This invention relates to the use of geranylgeranyl acetone (GGA), its isomers, and GGA derivatives in a method for for treating a disease in a subject mediated in part by miRNA-378 or miRNA-711 increased activity comprising administerin...  
WO/2014/106612A1
The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.  
WO/2014/106622A1
The present invention relates to new 1,2,3-triazole-amine derivatives of formula (I), having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising the...  
WO/2014/106988A1
The present invention relates to a method for protecting nerve cells from nerve cell death induced by kainic acid by pretreating nerve cells with anthocyanin, and to a composition comprising anthocyanin, as an active ingredient, for prot...  
WO/2014/103801A1
[Problem] To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. [Solution] This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an i...  
WO/2014/103475A1
The purpose of the present invention is to provide a skin-exterior anti-ageing composition for preventing or improving trouble areas upon the exterior of the skin caused by ageing and degradation such as wrinkles, fine lines, blotches, a...  
WO/2014/102417A1
The invention relates to a use of a compound of formula (I), or one of the salts thereof, wherein: R represents a linear or branched aliphatic chain selected from the group consisting of a C1-C16 saturated hydrocarbonated chain and a C2-...  
WO/2014/104171A1
The purpose of the present invention is to provide a skin-exterior anti-ageing composition for preventing or improving trouble areas upon the exterior of the skin caused by ageing and degradation such as wrinkles, fine lines, blotches, a...  
WO/2014/103481A1
Provided is a novel compound which has excellent Aβ aggregation inhibitory activity and is useful as a pharmaceutical product. A cyclic peptide comprising the amino acid sequence represented by formula (1), wherein an α-amino group at ...  
WO/2014/104757A1
The present invention relates to a compound selected from the group consisting of a compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, an ester, a prodrug, a hydrate, a solvate, and an isomer thereof,...  
WO/2014/100934A1
The compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds are provided. The methods of treating disea...  
WO/2014/105666A1
Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the...  
WO/2014/104220A1
The objective of the present invention is to provide a method for preventing denaturation by oxygen of drugs inside a patch that is enclosed in a packaging container. The present invention is a packaging comprising a packaging container ...  
WO/2014/104414A1
This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-be nzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibiter. The present invention provides a salt of compo...  
WO/2014/106050A1
This invention relates to compositions comprising lithium and methods of their use.  
WO/2014/101295A3
Disclosed is an isoxazole derivative that inhibits the activity of the Janus kinases (JAKs), the structure thereof as presented in formula I, formula II, formula IX, and formula XI. The substituent groups in the formulas are described in...  
WO/2014/102594A3
The disclosure relates to Substituted Benzimidazole-Type Piperidine Compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof, e.g., a pharmaceutically acceptable salt or solvate, wherein R1, R2, R3, Qa, W, U, A,...  
WO/2014/102090A1
The present invention concerns a pharmaceutical compound having the Formula (1), or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a cognitive, neurodegenerative or neuronal disorder disease such as...  
WO/2014/102780A1
This invention relates to the use Pulicaria incisa (Pi) infusion for granting cells and tissues with anti-oxidative effect. The invention further relates to the use Pulicaria incisa (Pi) infusion for treating neuroinflammatory conditions...  
WO/2014/102589A1
The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formule (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Q, Y1, Z, A, B, E, and a are as defined he...  
WO/2014/105870A1
Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telom...  
WO/2014/101120A1
Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.  
WO/2014/105620A1
Pregn-4-en-20-yn-3β-one is useful in the treatment of depressive disorders by nasal administration.  
WO/2014/102377A1
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the presen...  
WO/2014/102588A3
The disclosure relates to indole-type piperidine compounds, indoline-type piperidine compounds and related piperidine-type bicyclic compounds containing a five-membered nitrogen- containing ring (e.g., pyrrole or dihydropyrrole) fused to...  
WO/2014/101373A1
Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds whic...  
WO/2014/104272A1
The present invention provides a cinnamic acid amide derivative having an excellent analgesic activity. The cinnamic acid amide derivative according to the present invention is a compound that exhibits an excellent analgesic activity on ...  
WO/2014/104372A1
Provided is a novel α-halogen substituted thiophene compound which has strong LPA receptor antagonist activity and is useful as a pharmaceutical product, or a pharmacologically acceptable salt thereof. A compound represented by general ...  
WO/2014/101113A1
Disclosed are compounds of Formula (A), as defined herein, which have binding activity for an A2A-receptor and are believed to be useful for treatment or management of CNS diseases or conditions which can be treated or managed using comp...  
WO/2014/105576A1
Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids.  
WO/2014/102592A3
The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as of those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R20, R21, Q, Y1, Z, A, B,...  
WO/2014/102778A3
Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying a...  
WO/2014/106238A1
Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or manage...  
WO/2014/102339A1
The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H -benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions ...  
WO/2014/102233A1
The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). Th...  
WO/2014/101295A2
Disclosed is an isoxazole derivative that inhibits the activity of the Janus kinases (JAKs), the structure thereof as presented in formula I, formula II, formula IX, and formula XI. The substituent groups in the formulas are described in...  
WO/2014/097978A1
Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving the abnormal accumulation of amyloid β protein, which contains ILEI or a vector in which the polynucleotide encoding ILEI has been inserte...  
WO/2014/100227A1
Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and com...  
WO/2014/098831A1
Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen o...  
WO/2014/100601A2  
WO/2014/098306A1
The present invention relates to an acetylcholinesterase activity inhibitor, a pharmaceutical composition for preventing and/or treating dementia, and/or a cerebral nerve protective agent containing a compound derived from Hericium erina...  
WO/2014/100533A1
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  

Matches 451 - 500 out of 103,211